- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502628
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
Hyperbaric Oxygen Therapy for the Treatment of Hemorrhagic Cystitis Post Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for many malignant or nonmalignant hematological diseases. Hemorrhagic cystitis (HC) is one of the common and major causes of morbidity in patients undergoing allo-HSCT. Its incidence ranges from 7 to 52%, and its manifestations range from painless microscopic hematuria to severe bladder hemorrhage, leading to clot formation within the urinary tract and even renal failure. This complication results in much pain to the patient and increasing treatment cost.
Late-onset HC (two weeks after stem cell infusion) has been associated with reactivation of viruses, including cytomegalovirus, polyoma BK and JC viruses, and adenovirus types I and II. Former studies have confirmed that the bladder is also considered to be one of the immune attacked organs in acute graft-versus-host disease (aGVHD). The classic treatments for HC include hydration, alkalization, and bladder irrigation, immunosuppressant reduction, and platelet transfusion. Patients with viral infection may be treated with antiviral agents, but their efficacy is limited. When the HC was considered to be associated with aGVHD, some immunosuppressive agents such as glucocorticoids will be added in. However, too intensive immunosuppressive measures leave the patients susceptible to infection and, in turn, increases the accidence of non-relapse mortality (NRM). The mechanism underlying the development of HC remains largely unidentified, and its optimal treatment has not yet been established. It is important to explore novel, less-toxic, higher effective, and cost-effective strategies to improve HC.
The elevated levels of available oxygen and partial pressure of arterial oxygen provide the main benefits of Hyperbaric oxygen therapy (HBOT) in clinical practice that addresses these areas of inadequate or poor tissue healing. HBOT is utilized as primary or adjunctive therapy for many medical conditions in which tissue damage is triggered by hypoxic injury. The pharmacological and physiologic effects of HBOT have direct and indirect mechanisms and effects on reactive oxygen species (ROS) most beneficial to that of wound healing and antibacterial treatments. HBOT can stimulate fibroblast proliferation, angiogenesis, and wound healing. It has been shown effective in the treatment of radiation-induced HC by promoting fibroblast proliferation and capillary angiogenesis, decreasing edema, and facilitating damaged hypoxic urothelium. Based on the above clinical and pre-clinical practice, the investigators deduce that HBOT may benefit patients with HC after HSCT. In the investigators' limited early-onset investigation, the investigators found HBO was largely successful in 20 patients suffering HC post-allo-HSCT, showed a quick resolution or improvement of HC. The investigators also observed more rapid responses in patients who started HBOT earlier after the diagnosis of HC. The investigators confirmed that HBOT was effective and well-tolerated in the patients, regardless of the infective- or non-infective- caused HC. Therefore, the investigators design this prospective, randomized, and single-arm clinical trial to establish the definitive efficacy and safety of HBOT in patients with HC after allo-HSCT.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yujie M JIANG
- Phone Number: 8613370506886 8613370506886
- Email: yujiejiang05@126.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Recruiting
- Shandong Provincial Hospital
-
Contact:
- Yujie JIANG
- Phone Number: 8613370506886
- Email: yujiejiang05@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing allogeneic stem cell transplantation
- Patients develop late-onset hemorrhagic cystitis (HC)
- The count of neutrophilia cells over 0.5 * 10^9/L, hemoglobin over 60 g/L, platelet over 30 *10^9/L
- SGOT/SGPT no more than 2 times of UNL
- Serum creatinine no more than 1.5 times of UNL
- Signed informed consent
Exclusion Criteria:
- Early-onset HC post-allo-HSCT
- Unsuitable to the study due to severe complication such as uncontrolled severe infection
- Claustrophobia
- Ear diseases such as otitis media
- Eye diseases such as glaucoma
- Epilepsy history
- Important organ dysfunction
- Coagulopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HBOT group
Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined.
Then HBOT will be scheduled every day until symptoms of HC vanished.
|
Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined.
Then HBOT will be scheduled every day until symptoms of HC vanished.
Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate of HBOT
Time Frame: Six months post-allo-HSCT
|
Response rate of HBOT was determined on the basis of HC symptom disppearance and the normal urine routine test result
|
Six months post-allo-HSCT
|
Incidence and severity of treatment-related adverse events
Time Frame: 3 years
|
Number of participants with treatment-related adverse events and the the severity of these events.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory biomarker analysis
Time Frame: 3 years
|
Exploratory biomarker to predict treatment response
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Xin Wang, Shandong Provincial Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBOT for HC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stem Cell Transplant Complications
-
Peking University People's HospitalActive, not recruitingStem Cell Transplant ComplicationsChina
-
Massachusetts General HospitalCompletedStem Cell Transplant ComplicationsUnited States
-
Henry Ford Health SystemRecruitingStem Cell Transplant ComplicationsUnited States
-
University Hospital, EssenUniversity Of Perugia; Institut Paoli-Calmettes; Medical University of Warsaw; Universität... and other collaboratorsNot yet recruitingSurvivorship | Stem Cell Transplant Complications
-
Children's Hospital of PhiladelphiaRutgers University; NJ Dept of Health Commission on Cancer ResearchCompleted
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaMariarosaria Sessa, MD; Mario Arpinati, MD; Francesco Barbato, MDRecruitingAging | Stem Cell Transplant ComplicationsItaly
-
King Faisal Specialist Hospital and Research Centre...CompletedPulmonary Complication | Stem Cell Transplant ComplicationsSaudi Arabia
-
Radboud University Medical CenterEnrolling by invitationStem Cell Transplant Complications | Oral ComplicationNetherlands
-
Peking University People's HospitalUnknown
-
AHS Cancer Control AlbertaNot yet recruiting
Clinical Trials on Hyperbaric oxygen therapy
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia
-
Louisiana State University Health Sciences Center...U.S. Army Medical Research and Development CommandUnknownTraumatic Brain Injury | Post-Concussion SyndromeUnited States
-
Omar AljitawiCompleted
-
University of British ColumbiaUnknown
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
St. Joseph's Healthcare HamiltonUniversity Health Network, Toronto; Judy Dan Research and Treatment Centre...CompletedDiabetes Mellitus | Chronic Ulcers of the Lower LimbCanada
-
UMC UtrechtThe Netherlands Cancer InstituteCompletedBreast Cancer | Radiation ToxicityNetherlands
-
University of VersaillesAssistance Publique - Hôpitaux de ParisTerminatedCarbon Monoxide PoisoningFrance
-
Assaf-Harofeh Medical CenterUnknownChronic Renal FailureIsrael